Codomax Inc.

Codomax Inc. is a biotechnology company focused on developing innovative platforms for optimizing protein production and biologics manufacturing. The company has developed the EPI-MAX platform, an integrated omics and computational-based technology that leverages cellular stress responses to enhance protein expression and address challenges in biomanufacturing. Registered in SAM.gov as a for-profit corporate entity, Codomax specializes in advanced genetic and computational approaches to improve the efficiency of protein production across various cell systems.

Through its federal grant awards from the National Center for Advancing Translational Sciences (NCATS), Codomax has consistently received funding to develop sophisticated biotechnology solutions for complex protein manufacturing challenges. The company's recent grants, each valued around $350,000, have focused on optimizing protein expression in different cellular hosts, including Pichia pastoris and Chinese Hamster Ovary (CHO) cells. Specific project goals have included developing designer Pichia strains to express difficult-to-produce therapeutic proteins, enhancing antibody production by re-engineering transcription factors, and improving interferon yields through advanced codon engineering techniques. The research aims to address critical bottlenecks in biomanufacturing by using innovative approaches like stress-induced tRNA reprogramming, CRISPR-Cas9 gene editing, and systems-level analysis of cellular protein production mechanisms. These projects align with broader national biotechnology initiatives and demonstrate Codomax's commitment to advancing biologics manufacturing technologies.